Recurring large deletion in DRC1 (CCDC164) identified as causing primary ciliary dyskinesia in two Asian patients.


Journal

Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758

Informations de publication

Date de publication:
08 2019
Historique:
received: 22 02 2019
revised: 16 04 2019
accepted: 18 05 2019
pubmed: 5 7 2019
medline: 1 7 2020
entrez: 5 7 2019
Statut: ppublish

Résumé

Primary ciliary dyskinesia (PCD) is a relatively rare autosomal recessive or X-linked disorder affecting ciliary function. In the set of causative genes, however, predominant pathogenic variants remain unknown in Asia. A diagnosis of PCD was made following a modern comprehensive testing including genetic analysis; targeted resequencing for screening variants, and Sanger sequencing for determination of the breakpoints, with an additional review of databases to calculate the deletion frequency. A multiplexed PCR-based detection method has also been developed. We ascertained a 50-year-old Japanese male who had been diagnosed with diffuse panbronchiolitis (DPB), but refractory to macrolide therapy. We reevaluated the case and identified a large homozygous deletion spanning exons 1 to 4 of the DRC1 and determined the breakpoints (NM_145038.4: c.1-3952_540 + 1331del27748-bp). In the PCD cohort at the University of North Carolina, we found a female PCD patient of Korean descent harboring the same homozygous deletion. From the Invitae testing cohort, we extracted four carriers of the same deletion among 965 Asian individuals, whereas no deletion was found in the 23,951 non-Asians. We speculate that the DRC1 deletion is a recurrent or perhaps founder mutation in Asians. The simple PCR method could be a useful screening tool.

Sections du résumé

BACKGROUND
Primary ciliary dyskinesia (PCD) is a relatively rare autosomal recessive or X-linked disorder affecting ciliary function. In the set of causative genes, however, predominant pathogenic variants remain unknown in Asia.
METHOD
A diagnosis of PCD was made following a modern comprehensive testing including genetic analysis; targeted resequencing for screening variants, and Sanger sequencing for determination of the breakpoints, with an additional review of databases to calculate the deletion frequency. A multiplexed PCR-based detection method has also been developed.
RESULTS
We ascertained a 50-year-old Japanese male who had been diagnosed with diffuse panbronchiolitis (DPB), but refractory to macrolide therapy. We reevaluated the case and identified a large homozygous deletion spanning exons 1 to 4 of the DRC1 and determined the breakpoints (NM_145038.4: c.1-3952_540 + 1331del27748-bp). In the PCD cohort at the University of North Carolina, we found a female PCD patient of Korean descent harboring the same homozygous deletion. From the Invitae testing cohort, we extracted four carriers of the same deletion among 965 Asian individuals, whereas no deletion was found in the 23,951 non-Asians.
CONCLUSION
We speculate that the DRC1 deletion is a recurrent or perhaps founder mutation in Asians. The simple PCR method could be a useful screening tool.

Identifiants

pubmed: 31270959
doi: 10.1002/mgg3.838
pmc: PMC6687623
doi:

Substances chimiques

DRC1 protein, human 0
Microtubule-Associated Proteins 0

Types de publication

Case Reports Journal Article Observational Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e838

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL071798
Pays : United States
Organisme : NCATS NIH HHS
ID : U2C TR002818
Pays : United States
Organisme : NHLBI NIH HHS
ID : U54 HL096458
Pays : United States

Informations de copyright

© 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.

Références

Clin Chest Med. 2016 Sep;37(3):449-61
pubmed: 27514592
Am J Respir Crit Care Med. 2018 Jun 15;197(12):e24-e39
pubmed: 29905515
Ultrastruct Pathol. 2017 Nov-Dec;41(6):373-385
pubmed: 28915070
Auris Nasus Larynx. 2018 Jun;45(3):585-591
pubmed: 28939216
Nat Genet. 2013 Mar;45(3):262-8
pubmed: 23354437
Am J Hum Genet. 2000 Feb;66(2):501-7
pubmed: 10677310
Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1829-32
pubmed: 9620913
Mol Genet Genomic Med. 2019 Aug;7(8):e838
pubmed: 31270959
Respirology. 2011 May;16(4):581-8
pubmed: 21303426

Auteurs

Kozo Morimoto (K)

Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan.

Minako Hijikata (M)

The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan.

Maimoona A Zariwala (MA)

Department of Pathology and Laboratory Medicine and Marsico Lung Institute, University of North Carolina School of Medicine, Chapel Hill, North Carolina.

Keith Nykamp (K)

Invitae, San Francisco, California.

Atsushi Inaba (A)

The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan.

Tz-Chun Guo (TC)

The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan.

Hiroyuki Yamada (H)

The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan.

Rebecca Truty (R)

Invitae, San Francisco, California.

Yuka Sasaki (Y)

Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.

Ken Ohta (K)

Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.

Shoji Kudoh (S)

Japan Anti-Tuberculosis Association, Tokyo, Japan.

Margaret W Leigh (MW)

Department of Pediatrics and Marsico Lung Institute, University of North Carolina School of Medicine, Chapel Hill, North Carolina.

Michael R Knowles (MR)

Department of Medicine and Marsico Lung Institute, University of North Carolina School of Medicine, Chapel Hill, North Carolina.

Naoto Keicho (N)

The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH